

International Journal of Medical Sociology and Anthropology ISSN 2756-3820 Vol. 12 (2), pp. 001-006, February, 2023. Available online at www.internationalscholarsjournals.org © International Scholars Journals

Author(s) retain the copyright of this article.

Review

Potentially malignant lesion – oral leukoplakia

Prasanna Kumar Rao J

Associate Professor, Oral Medicine and Radiology, Yenepoya Dental College, Yenepoya University, University Road, Nithyananda Nagar Post, Mangalore – 575018, Karnataka, India Email: drjpkrao@gmail.com, Mobile: +91 9900151108

Accepted 06 September, 2022

Leukoplakia was considered as one of the premalignant lesion but now it was included under potentially malignant disorder. It is mainly associated with chewing and smoking tobacco habits. It has a risk of malignant transformation if the risk factors are not eliminated. In this review we discussed the classification, clinical features, malignant potential and various treatment modalities of oral Leukoplakia.

Keywords: Leukoplakia, Homogenous, Speckled.

INTRODUCTION

Oral premalignancy is considered as Intermediate stage. There are two types; they are premalignant lesions and premalignant conditions. Premalignant Lesions are defined as 'A localized area of morphologycally altered tissue in which cancer is more likely to occur'. Example is Leukoplakia. Premalignant Conditions are defined as 'A generalized state for predisposition of malignancy'. Example is Oral submucous fibrosis. But recently WHO considering both premalignant lesions and conditions under a single group of desorders that is "Potentially Malignant Disorders" (Warnakulasuriya et al., 2007).: (leuko white; plakia patch) Leukoplakia is considered as one of the most common premalignant lesion or Potentially Malignant Disorder (van der Waal et al, 1997). According to WHO, it is defined as white lesions that cannot be characterized as being a result of any other specific disease of the oral mucosa (Seo et al., 2010). Risk factors include, tobacco- chewing and smoking, cigar / cigarette / beedi / pipe, alcohol, chronic trauma, candidiasis, galvanism, syphilis, vit deficiency, infections, bacterial, fungal, viral, ultra violet light, hormonal disturbances. (Haris CM)

There was a study conducted in china which reveals the prevalence in smokers was 23.43% and in non-smokers 1.93%. Among three variants of smoking, the traditional Hanyan pipe smoking carried the highest risk for the development of Oral Leukoplakia followed by cigarette and Shuiyan water pipe smoking. The rate of alcohol drinkers with OL was 54.50% and 22.21% in individuals without Oral Leukoplakia (Zhang et al., 2010).

Classification

There are different clinical types in oral leukoplakias. They are as follows (Bailoor and Nagesh, 2005),

- Speckeled leukoplakia and non speckeled leukoplakia
- Homogenous, Ulcerative, Speckeled
- Reversible / irreversible

It is also clinically classified in to six types.

- Thin or mild leukoplakia
- Thick or homogenous Leukoplakia (Figure 1)
- Nodular / granular leukoplakia
- Verrucous Leukoplakia (Figure 3)



Figure 1. Homogenous leukoplakia



Figure 2. Speckeled leukoplakia



Figure 3. Proliferative verrucous Leukoplakia

- Proliferative verrucous leukoplakia
- Speckeled leukoplakia (Figure 2)

Clinical features

- Age: It occur in persons in their fifth to seventh decade of life. Approximately 80% of patients are older than 40 years.

- sex: Comparitively more in males with a male-to-female ratio of 2:1 (Cawson and Odell., 1998).
- site: Common site in the oral cavity are Lip, Vestibule, BM, Gingiva, and Tongue. More commonly in beedi smokers it presents in Anterior buccal mucosa and patients with chewing habits it is seen on the Posterior buccal mucosa. Individuals with oral leukoplakia are not symptomatic (Cawson and Odell, 1998)

- colour: clinically it appears gray, white or yellowish white
- thickness: it may be thin or thick
- appearance: it appears Fissure, Granular, Patch, Plaque, Verruciform or Erythematous.
- stages: Clinically there are three stages are described. In early stage lesion is nonpalpable, faintly translucent, with white discoloration. Next stage localized or diffuse, slightly elevated plaques with an irregular outline. These lesions are opaque white with fine, granular texture. Later in some instances, the lesions progress to thickened, white lesions, showing induration, fissuring, and ulcer formation.
- size: Varies from few millimeters to few centimeters
- shape is Irregular
- nonscrapable

Diagnosis: This type of lesions is diagnosed depending on clinical history and examination however the biopsy is necessary to confirm the diagnosis before starting any treatment plan. Tolludine blue and vizelite are used to select the biopsy site. In case of small lesions excisional biopsy is indicated and in large lesions incisional biopsy including the adjacent normal tissue is needed.

Histopathology: The main histopathological changes are (Liu et al, 2010),

- Keratinization of the epithelium (Hyperortho keratinization or Hyperpara keratinization)
- Increased thickness of epithelium Acanthosis
- Basement membrane becomes thin
- Inflammatory component in Connective Tissue
- Change in cellular layer
- -- Increased nuclear cytoplasmic ratio
- -- Hyperchromatic nuclei
- -- Nuclear hyperplasia
- -- Abnormal mitotic figures
- -- Increased mitosis
- -- Pleomorphic nuclei
- -- Basillar hyperplasia
- -- Drop shaped rete pegs (Figure 7)
- -- Loss of polarity

L C P STAGING: (L size C Clinical P Pathological) (Bailoor and Nagesh, 2005).

Resently the Leukoplakia was graded according to size, clinical and pathological stages it is known as LCP Staging.

- L xsize not specified
- L 1less than 2cm, single/ multiple
- L 22 to 4 cm, single/ multiple
- L 3more than 4cm, single/ multiple
- C 1Homogenous C 2Non homogenous
- P xNot specified
- P 0No epithelial dysplasia
- P 1distinct epithelial dysplasia

	Pathological	Clinical
STAGE 1	L1 P0	L1 C1
STAGE 2	L2 P0	L2 C1
STAGE 3	L3 P0	L3 C1
STAGE 4	L3 P1	L3 C2

Malignant potential

Oral leukoplakia is considered to be one of the common potentially malignant lesions of the oral mucosa, with a malignant transformation rate in various studies and locations that range from 0.6 to 20%.

- It is more in females (6%) than male (3.9%)
- More in patients with chewing tobacco habit.
- Oral Leukoplakia among non smokers have an increased rate of malignant transformation.
- Epithelial Dysplasia: Moderate and severe dysplastic lesions had a higher risk of malignant transformation than Oral Leukoplakia with or without epithelial dysplasia (Figure 4,5,6).
- Site: lesions in the floor of mouth, ventrolateral tongue and soft palate have a high risk of malignant transformation. Buccal Mucosa and commissures up to 1.8%, Lip and tongue 16% to 38.8%.

Five clinical criteria demonstrate a particularly high risk of malignant change. They are (Haris CM)

- The verrucous type is considered high risk.
- Erosion or ulceration within the lesion is highly suggestive of malignancy.
- The presence of a nodule indicates malignant potential.
- A lesion that is hard in its periphery is predictive of malignant change.
- Oral Leukoplakia of the anterior floor of the mouth and undersurface of the tongue is strongly associated with malignant potential. (Einhorn and Wersall, 1967; Haya-Fernández et al., 2004; Napier and Speight, 2008; Zhang et al., 2001; van der Waal, 2009; Reibel, 2003)

Differential diagnosis

Differential diagnosis considered are (Haris CM)

- Lichen planus
- Chemical burn
- Leukoedema
- White sponge nevus
- Discoid lupus erythematosis
- Syphilitic mucous patch
- Veruca vulgaris
- Cheek bite

Guidelines for treatment

We have to follow the following guidelines during treatment of Leukoplakia. They are, (Jeong et al., 2011)

- Elimination of risk factors like alcohol and Smoking and advise Nicotine substitutes. Enameloplasty in case of any brocken sharp tooth and replace faulty metal restoration.
- Biopsy is a must before any treatment plans

Should consider Conservative and surgical treatment, if the lesion do not heal in 2 to 3 weeks after elimination of risk factor.

High risk lesion requires excision of the lesion with follow-up



Figure 4. Mild dysplasia




Figure 5. Moderate dysplasia




Figure 6. Severe dysplasia




Figure 7. Drop shaped retepegs

- Reexamination of the patient every six months.
- Re-biopsy is required after 5 to 6 months to rule out any recurrence and dysplasia.

Nicotine substitutes: There are few nicotine substitutes are available such as Nicotine PATCH (Nicotinell and Novartis -Transdermal patches), Nicotine chewing gums (Nicorette), Nicotine spray and Nicotine inhaler which can be used to stop the habits.

Conservative treatment

The conservative treatment includes (Lippman et al., 1993; Garewal et al., 1999; Naidu, 2003; Azulay and Azulay, 1999).


- Vitamin theraphy (Vitamin C, Vitamin E, 13-cis – Retinoic acid and Vitamin B Complex) - Current recommended daily allowance for ascorbic acid ranges between 100–120 mg/per day for adults, daily intake of at least 140 mg/day is required for smokers because they usually present a reduction of the L-Ascorbic acid concentration in serum leukocytes. Dosage of vitamin E was 800 IU/day from 6 to 9months. In the systemic use with dosage of 300.000 IU of retinoic acid (Vitamin A), a clinical resolution of the 50% has been demonstrated. In topical use with dosage range from 0.05% to 1% a

clinical resolution from 10% to 27% has been obtained - Beeta-carotene and lycopene - Dosage of beta-carotene is 20 to 90mg/day with time periods from 3 to 12 months and lycopene was 4 to 8 mg/day.

- Antioxidants
- Nystatin theraphy to prevent any secondary fungal infections.

Surgical treatment

- CONVENTIONAL SURGERY to remove the lesions surgically.
- CRYOSURGERY Tissue exposed to extreme cold to produce irreversible cell damage. Cell death occurs at 20 degree centigrade. Cryoprobe refrigerated by liquid nitrogen (Lin et al., 2011).
- ELECTROCAUTERY Tissue distruction by high voltage current. Main advantage is less bleeding. And disadvantages are Foul odor, Hazarda of explosion, Under LA or GA, Slow healing, Pain and Scar (Jeong et al., 2011).
- CO2 LASER Commonly used in case of leukoplakia. CO2 Lasers contain CO2, nitrogen and helium gases. Cutting large surface area. Nd:YAG lasers also used (Chu et al., 1988).



TREATMENT FLOW CHART

CONCLUSION

Oral Leukoplakia is one of the potentially malignant disorders. This can be diagnosed with the clinical history and examination. Biopsy of such lesions is important before starting any treatment because there are many white lesions which look like Leukoplakia so rule out such lesions are very important.

REFERENCES

- Warnakulasuriya S, Johnson NW, van der Waal I (2007). Nomenclature and classification of potentially malignant disorders of the oral mucosa. J Oral Pathol Med. 36:575-580.
- van der Waal I, Schepman KP, van der Meij EH, Smeele LE (1997).
 Oral leukoplakia: a clinicopathological review. Oral Oncol. 33(5):291-301
- Seo J, Utumi ER, Zambon CE, Pedron IG, Ceccheti MM (2010). Use of retinoids in the treatment of oral Leukoplakia: Review. Rev Clín Pesq Odontol. maio/ago. 6(2):149-54
- Haris CM. Oral Leukoplakia http://emedicine.medscape.com/article/853864-overview.
- Zhang X, Li C, Song Y, Reichart PA (2010). Oral leukoplakia in China: a review. Oral Maxillofac Surg. 14(4):195-202.
- Bailoor DN, Nagesh KS (2005). Fundamentals of oral medicine and radiology. chapter 12. First edition. Jaypee brothers medical publishers. New Delhi.
- Cawson RA, Odell EW (1998). Essentials of Oral Pathology and Oral Medicine. 6th ed. New York, NY: Churchill Livingstone.
- Liu et al. (2010). Malignant transformation of oral leukoplakia: a retrospective cohort study of 218 Chinese patients. BMC Cancer. 10:685.
- Einhorn J, Wersall J (1967). Incidence of oral carcinoma in patients with leukoplakia of the oral mucosa. Cancer. 20(12):2189-93

- Haya-Fernández MC, Bagán JV, Murillo-Cortés J, Poveda-Roda R, Calabuig C (2004). The prevalence of oral leukoplakia in 138 patients with oral squamous cell carcinoma. Oral Dis. 10(6):346-8.
- Napier SS, Speight PM (2008). "Natural history of potentially malignant oral lesions and conditions: an overview of the literature," Journal of Oral Pathology and Medicine. 37(1):1–10.
- Zhang L, Cheung Jr KJ, Lam WL (2001). "Increased genetic damage in oral leukoplakia from high risk sites: potential impact on staging and clinical management," Cancer. 91: (11)2148–2155
- van der Waal I (2009). "Potentially malignant disorders of the oral and oropharyngeal mucosa; terminology, classification and present concepts of management," Oral Oncology. 45(4-5):317–323.
- Reibel J (2003). "Prognosis of oral pre-malignant lesions: significance of clinical, histopathological, andmolecular biological characteristics," Critical Reviews inOral Biology and Medicine. 14:(1):47–62.
- Jeong WJ, Paik JH, Cho SW, Sung MW, Kim KH, Ahn SH (2011). Excisional biopsy for management of lateral tongue leukoplakia. J Oral Pathol Med. Nov 12.
- Lippman SM, Batsakis JG, Toth BB, Weber RS, Lee JJ, Martin JW (1993). Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis. N Engl J Med. 328(1):15-20. Jan 7
- Garewal HS, Katz RV, Meyskens F, Pitcock J, Morse D, Friedman S (1999). Beta-carotene produces sustained remissions in patients with oral leukoplakia: results of a multicenter prospective trial. Arch Otolaryngol Head Neck Surg. 125(12):1305-10.
- Naidu KA (2003). "Vitamin C in human health and disease is still a mystery? An overview," Nutrition J . 2: 1–10.
- Azulay RD, Azulay DR (1999). "Atualizac, ao em Retin oides," in Dermatologia, Guanabara-Koogan Publishing, Rio de Janeiro, Brazil, 2nd edition. p. 516
- Lin HP, Chen HM, Cheng SJ, Yu CH, Chiang CP (2011). Cryogun cryotherapy for oral leukoplakia. Head Neck. Nov 15.
- Chu FW, Silverman S Jr, Dedo HH (1988). CO2 laser treatment of oral leukoplakia. Laryngoscope.98(2):125-30.